Gilead may soon be bringing a new cocktail of HIV drugs to market. The company said Monday that a combination of two drugs achieved non-inferiority

Aviceda Therapeutics is pushing forward with Phase 3 plans for its experimental eye drug despite failing a Phase 2b study in geographic atrophy. The mid-stage

Palvella Therapeutics said its drug candidate for a rare skin disease that affects children has yielded positive results in a mid-stage trial. The biotech’s gel

InnoCare Pharma’s experimental oral BTK inhibitor, called orelabrutinib, succeeded in a mid-stage trial in systemic lupus erythematosus (SLE), the Chinese biotech said Sunday. After nearly

Areteia Therapeutics, one of the biotech industry’s biggest recent startup bets in respiratory illness, has decided to wind down, according to a source familiar with